- Home
- PCVX vs AFRM Comparison
PCVX vs AFRM Comparison
Compare PCVX & AFRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | AFRM |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 14.3B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PCVX | AFRM |
|---|---|---|
| Price | $51.04 | $73.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 25 |
| Target Price | ★ $88.25 | $84.52 |
| AVG Volume (30 Days) | 1.6M | ★ 5.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 108.98 |
| EPS | N/A | ★ 0.90 |
| Revenue | N/A | ★ $3,224,412,000.00 |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $23.95 |
| P/E Ratio | ★ N/A | $81.17 |
| Revenue Growth | N/A | ★ 38.80 |
| 52 Week Low | $29.10 | $42.10 |
| 52 Week High | $65.00 | $100.00 |
Technical Indicators
Market Signals| Indicator | PCVX | AFRM |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 66.82 |
| Support Level | $41.52 | $71.42 |
| Resistance Level | $56.04 | $79.17 |
| Average True Range (ATR) | 1.97 | 3.80 |
| MACD | 0.17 | 0.33 |
| Stochastic Oscillator | 55.03 | 92.14 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
About AFRM Affirm Holdings Inc.
Founded in 2012, Affirm is a market leader in the buy-now, pay-later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also comprise the majority of its revenue. Affirm operates in the United States, which accounted for more than 95% of its revenue in 2025, but the firm has also expanded to Canada and the United Kingdom.